0
USD
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Opioid-Induced Constipation Market Insights, Forecast to 2025
Published Date: May 2019
|
Report Code: QYRE-Auto-716
Home | Category |Health |Pharmacy |Drugs & Medications
Global Opioid Induced Constipation Market Insights Forecast to 2025

Global Opioid-Induced Constipation Market Insights, Forecast to 2025

Code: QYRE-Auto-716
Report
May 2019
114 Pages
QYResearch
Region: Global, Europe, North America, Middle East, Asia Pacific,
Description
Table of Content
Tables & Figures
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
In the last several years, global market of Opioid-Induced Constipation developed smoothly, with an average growth rate of 3.85% from the forecast period 2019 to 2025.
The classification of Opioid-Induced Constipation includes Methylnaltrexone Bromide, Lubiprostone, Naloxegol and other OTC drugs. The revenue proportion of Lubiprostone in 2017 is about 33%, and the proportion of OTC drugs is in about 34%.
Opioid-Induced Constipation is widely sold in Hospital, Pharmacy and other field. The most proportion of Opioid-Induced Constipation is sold in Pharmacy, and the proportion in 2017 is 45.99%.
The global Opioid-Induced Constipation market is valued at 2240 million US$ in 2018 and will reach 3060 million US$ by the end of 2025, growing at a CAGR of 4.6% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Opioid-Induced Constipation market based on company, product type, end user and key regions.

This report studies the global market size of Opioid-Induced Constipation in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Opioid-Induced Constipation in these regions.
This research report categorizes the global Opioid-Induced Constipation market by top players/brands, region, type and end user. This report also studies the global Opioid-Induced Constipation market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
    Takeda Pharmaceuticals
    Bayer
    Sanofi
    Mallinckrodt
    Salix (Bausch Health)
    AstraZeneca
    Progenics Pharmaceuticals
    Purdue Pharm
    Nektar Therapeutics
    Daiichi Sankyo
    Prestige
    GSK
    Shionogi

Market size by Product
    Methylnaltrexone Bromide
    Lubiprostone
    Naloxegol
    Others
Market size by End User
    Hospital
    Pharmacy

Market size by Region
    North America
        United States
        Canada
        Mexico
    Asia-Pacific
        China
        India
        Japan
        South Korea
        Australia
        Indonesia
        Singapore
        Malaysia
        Philippines
        Thailand
        Vietnam
    Europe
        Germany
        France
        UK
        Italy
        Spain
        Russia
    Central & South America
        Brazil
        Rest of Central & South America
    Middle East & Africa
        GCC Countries
        Turkey
        Egypt
        South Africa

The study objectives of this report are:
    To study and analyze the global Opioid-Induced Constipation market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
    To understand the structure of Opioid-Induced Constipation market by identifying its various subsegments.
    To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
    Focuses on the key global Opioid-Induced Constipation companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
    To project the value and sales volume of Opioid-Induced Constipation submarkets, with respect to key regions.
    To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Opioid-Induced Constipation are as follows:
    History Year: 2014-2018
    Base Year: 2018
    Estimated Year: 2019
    Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Opioid-Induced Constipation market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents

1 Study Coverage
    1.1 Opioid-Induced Constipation Product
    1.2 Market Segments
    1.3 Key Manufacturers Covered
    1.4 Market by Type
        1.4.1 Global Opioid-Induced Constipation Market Size Growth Rate by Product
        1.4.2 Methylnaltrexone Bromide
        1.4.3 Lubiprostone
        1.4.4 Naloxegol
        1.4.5 Others
    1.5 Market by End User
        1.5.1 Global Opioid-Induced Constipation Market Size Growth Rate by End User
        1.5.2 Hospital
        1.5.3 Pharmacy
    1.6 Study Objectives
    1.7 Years Considered

2 Executive Summary
    2.1 Global Opioid-Induced Constipation Market Size
        2.1.1 Global Opioid-Induced Constipation Revenue 2014-2025
        2.1.2 Global Opioid-Induced Constipation Sales 2014-2025
    2.2 Opioid-Induced Constipation Growth Rate by Regions
        2.2.1 Global Opioid-Induced Constipation Sales by Regions
        2.2.2 Global Opioid-Induced Constipation Revenue by Regions

3 Breakdown Data by Manufacturers
    3.1 Opioid-Induced Constipation Sales by Manufacturers
        3.1.1 Opioid-Induced Constipation Sales by Manufacturers
        3.1.2 Opioid-Induced Constipation Sales Market Share by Manufacturers
        3.1.3 Global Opioid-Induced Constipation Market Concentration Ratio (CR5 and HHI)
    3.2 Opioid-Induced Constipation Revenue by Manufacturers
        3.2.1 Opioid-Induced Constipation Revenue by Manufacturers (2014-2019)
        3.2.2 Opioid-Induced Constipation Revenue Share by Manufacturers (2014-2019)
    3.3 Opioid-Induced Constipation Price by Manufacturers
    3.4 Opioid-Induced Constipation Manufacturing Base Distribution, Product Types
        3.4.1 Opioid-Induced Constipation Manufacturers Manufacturing Base Distribution, Headquarters
        3.4.2 Manufacturers Opioid-Induced Constipation Product Type
        3.4.3 Date of International Manufacturers Enter into Opioid-Induced Constipation Market
    3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
    4.1 Global Opioid-Induced Constipation Sales by Product
    4.2 Global Opioid-Induced Constipation Revenue by Product
    4.3 Opioid-Induced Constipation Price by Product

5 Breakdown Data by End User
    5.1 Overview
    5.2 Global Opioid-Induced Constipation Breakdown Data by End User

6 North America
    6.1 North America Opioid-Induced Constipation by Countries
        6.1.1 North America Opioid-Induced Constipation Sales by Countries
        6.1.2 North America Opioid-Induced Constipation Revenue by Countries
        6.1.3 United States
        6.1.4 Canada
        6.1.5 Mexico
    6.2 North America Opioid-Induced Constipation by Product
    6.3 North America Opioid-Induced Constipation by End User

7 Europe
    7.1 Europe Opioid-Induced Constipation by Countries
        7.1.1 Europe Opioid-Induced Constipation Sales by Countries
        7.1.2 Europe Opioid-Induced Constipation Revenue by Countries
        7.1.3 Germany
        7.1.4 France
        7.1.5 UK
        7.1.6 Italy
        7.1.7 Russia
    7.2 Europe Opioid-Induced Constipation by Product
    7.3 Europe Opioid-Induced Constipation by End User

8 Asia Pacific
    8.1 Asia Pacific Opioid-Induced Constipation by Countries
        8.1.1 Asia Pacific Opioid-Induced Constipation Sales by Countries
        8.1.2 Asia Pacific Opioid-Induced Constipation Revenue by Countries
        8.1.3 China
        8.1.4 Japan
        8.1.5 Korea
        8.1.6 India
        8.1.7 Australia
        8.1.8 Indonesia
        8.1.9 Malaysia
        8.1.10 Philippines
        8.1.11 Thailand
        8.1.12 Vietnam
        8.1.13 Singapore
    8.2 Asia Pacific Opioid-Induced Constipation by Product
    8.3 Asia Pacific Opioid-Induced Constipation by End User

9 Central & South America
    9.1 Central & South America Opioid-Induced Constipation by Countries
        9.1.1 Central & South America Opioid-Induced Constipation Sales by Countries
        9.1.2 Central & South America Opioid-Induced Constipation Revenue by Countries
        9.1.3 Brazil
    9.2 Central & South America Opioid-Induced Constipation by Product
    9.3 Central & South America Opioid-Induced Constipation by End User

10 Middle East and Africa
    10.1 Middle East and Africa Opioid-Induced Constipation by Countries
        10.1.1 Middle East and Africa Opioid-Induced Constipation Sales by Countries
        10.1.2 Middle East and Africa Opioid-Induced Constipation Revenue by Countries
        10.1.3 GCC Countries
        10.1.4 Turkey
        10.1.5 Egypt
        10.1.6 South Africa
    10.2 Middle East and Africa Opioid-Induced Constipation by Product
    10.3 Middle East and Africa Opioid-Induced Constipation by End User

11 Company Profiles
    11.1 Takeda Pharmaceuticals
        11.1.1 Takeda Pharmaceuticals Company Details
        11.1.2 Company Business Overview
        11.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
        11.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Products Offered
        11.1.5 Takeda Pharmaceuticals Recent Development
    11.2 Bayer
        11.2.1 Bayer Company Details
        11.2.2 Company Business Overview
        11.2.3 Bayer Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
        11.2.4 Bayer Opioid-Induced Constipation Products Offered
        11.2.5 Bayer Recent Development
    11.3 Sanofi
        11.3.1 Sanofi Company Details
        11.3.2 Company Business Overview
        11.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
        11.3.4 Sanofi Opioid-Induced Constipation Products Offered
        11.3.5 Sanofi Recent Development
    11.4 Mallinckrodt
        11.4.1 Mallinckrodt Company Details
        11.4.2 Company Business Overview
        11.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
        11.4.4 Mallinckrodt Opioid-Induced Constipation Products Offered
        11.4.5 Mallinckrodt Recent Development
    11.5 Salix (Bausch Health)
        11.5.1 Salix (Bausch Health) Company Details
        11.5.2 Company Business Overview
        11.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
        11.5.4 Salix (Bausch Health) Opioid-Induced Constipation Products Offered
        11.5.5 Salix (Bausch Health) Recent Development
    11.6 AstraZeneca
        11.6.1 AstraZeneca Company Details
        11.6.2 Company Business Overview
        11.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
        11.6.4 AstraZeneca Opioid-Induced Constipation Products Offered
        11.6.5 AstraZeneca Recent Development
    11.7 Progenics Pharmaceuticals
        11.7.1 Progenics Pharmaceuticals Company Details
        11.7.2 Company Business Overview
        11.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
        11.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Products Offered
        11.7.5 Progenics Pharmaceuticals Recent Development
    11.8 Purdue Pharm
        11.8.1 Purdue Pharm Company Details
        11.8.2 Company Business Overview
        11.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
        11.8.4 Purdue Pharm Opioid-Induced Constipation Products Offered
        11.8.5 Purdue Pharm Recent Development
    11.9 Nektar Therapeutics
        11.9.1 Nektar Therapeutics Company Details
        11.9.2 Company Business Overview
        11.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
        11.9.4 Nektar Therapeutics Opioid-Induced Constipation Products Offered
        11.9.5 Nektar Therapeutics Recent Development
    11.10 Daiichi Sankyo
        11.10.1 Daiichi Sankyo Company Details
        11.10.2 Company Business Overview
        11.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
        11.10.4 Daiichi Sankyo Opioid-Induced Constipation Products Offered
        11.10.5 Daiichi Sankyo Recent Development
    11.11 Prestige
    11.12 GSK
    11.13 Shionogi

12 Future Forecast
    12.1 Opioid-Induced Constipation Market Forecast by Regions
        12.1.1 Global Opioid-Induced Constipation Sales Forecast by Regions 2019-2025
        12.1.2 Global Opioid-Induced Constipation Revenue Forecast by Regions 2019-2025
    12.2 Opioid-Induced Constipation Market Forecast by Product
        12.2.1 Global Opioid-Induced Constipation Sales Forecast by Product 2019-2025
        12.2.2 Global Opioid-Induced Constipation Revenue Forecast by Product 2019-2025
    12.3 Opioid-Induced Constipation Market Forecast by End User
    12.4 North America Opioid-Induced Constipation Forecast
    12.5 Europe Opioid-Induced Constipation Forecast
    12.6 Asia Pacific Opioid-Induced Constipation Forecast
    12.7 Central & South America Opioid-Induced Constipation Forecast
    12.8 Middle East and Africa Opioid-Induced Constipation Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
    13.1 Market Opportunities and Drivers
    13.2 Market Challenges
    13.3 Market Risks/Restraints
    13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
    14.1 Value Chain Analysis
    14.2 Opioid-Induced Constipation Customers
    14.3 Sales Channels Analysis
        14.3.1 Sales Channels
        14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
    16.1 Research Methodology
        16.1.1 Methodology/Research Approach
        16.1.2 Data Source
    16.2 Author Details
    16.3 Disclaimer
List of Tables and Figures

    Figure Opioid-Induced Constipation Product Picture
    Table Opioid-Induced Constipation Market Segments
    Table Key Manufacturers Opioid-Induced Constipation Covered
    Table Global Opioid-Induced Constipation Market Size Growth Rate by Product 2019-2025 (K Units) & (Million US$)
    Figure Global Opioid-Induced Constipation Sales Market Share by Product 2014-2025
    Figure Methylnaltrexone Bromide Product Picture
    Table Major Manufacturers of Methylnaltrexone Bromide
    Figure Lubiprostone Product Picture
    Table Major Manufacturers of Lubiprostone
    Figure Naloxegol Product Picture
    Table Major Manufacturers of Naloxegol
    Figure Others Product Picture
    Table Major Manufacturers of Others
    Table Global Opioid-Induced Constipation Market Size Growth Rate by End User 2019-2025 (K Units)
    Figure Hospital
    Figure Pharmacy
    Figure Opioid-Induced Constipation Report Years Considered
    Figure Global Opioid-Induced Constipation Market Size 2014-2025 (Million US$)
    Figure Global Opioid-Induced Constipation Sales 2014-2025 (K Units)
    Table Global Opioid-Induced Constipation Market Size by Regions 2014-2019 (K Units) & (Million US$)
    Table Global Opioid-Induced Constipation Sales by Regions 2014-2019 (K Units)
    Table Global Opioid-Induced Constipation Sales Market Share by Regions 2014-2019
    Figure Global Opioid-Induced Constipation Sales Market Share by Regions 2014-2019
    Figure 2018 Global Opioid-Induced Constipation Sales Market Share by Regions
    Table Global Opioid-Induced Constipation Revenue by Regions 2014-2019 (Million US$)
    Table Global Opioid-Induced Constipation Revenue Market Share by Regions 2014-2019
    Figure Global Opioid-Induced Constipation Revenue Market Share by Regions 2014-2019
    Figure 2018 Global Opioid-Induced Constipation Revenue Market Share by Regions
    Table Global Opioid-Induced Constipation Sales by Manufacturers (2014-2019) (K Units)
    Table Global Opioid-Induced Constipation Sales Share by Manufacturers (2014-2019)
    Figure Global Opioid-Induced Constipation Sales Share by Manufacturers in 2018
    Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table Opioid-Induced Constipation Revenue by Manufacturers (2014-2019) (Million USD)
    Table Opioid-Induced Constipation Revenue Share by Manufacturers (2014-2019)
    Figure Opioid-Induced Constipation Value Share by Manufacturers in 2018
    Table Key Manufacturers Opioid-Induced Constipation Price (2014-2019) (USD/Unit)
    Table Opioid-Induced Constipation Manufacturers Manufacturing Base Distribution and Headquarters
    Table Manufacturers Opioid-Induced Constipation Product Type
    Table Date of International Manufacturers Enter into Opioid-Induced Constipation Market
    Table Manufacturers Mergers & Acquisitions, Expansion Plans
    Table Global Opioid-Induced Constipation Sales by Product (2014-2019) (K Units)
    Table Global Opioid-Induced Constipation Sales Share by Product (2014-2019)
    Figure Global Opioid-Induced Constipation Sales Market Share by Product (2014-2019)
    Figure Global Opioid-Induced Constipation Sales Market Share by Product in 2018
    Table Global Opioid-Induced Constipation Revenue by Product (2014-2019) (Million US$)
    Table Global Opioid-Induced Constipation Revenue Share by Product (2014-2019)
    Figure Global Opioid-Induced Constipation Revenue Market Share by Product (2014-2019)
    Figure Global Opioid-Induced Constipation Revenue Market Share by Product in 2018
    Table Opioid-Induced Constipation Price by Product 2014-2019 (USD/Unit)
    Table Global Opioid-Induced Constipation Sales by End User (2014-2019) (K Units)
    Table Global Opioid-Induced Constipation Sales Share by End User (2014-2019)
    Figure Global Sales Opioid-Induced Constipation Market Share by End User (2014-2019)
    Figure Global Sales Opioid-Induced Constipation Market Share by End User in 2018
    Figure North America Opioid-Induced Constipation Sales Growth Rate 2014-2019 (K Units)
    Figure North America Opioid-Induced Constipation Revenue Growth Rate 2014-2019 (Million US$)
    Table North America Opioid-Induced Constipation Sales by Countries (2014-2019) (K Units)
    Table North America Opioid-Induced Constipation Sales Market Share by Countries (2014-2019)
    Figure 2018 North America Opioid-Induced Constipation Sales Market Share by Countries
    Table North America Opioid-Induced Constipation Revenue by Countries (2014-2019) (Million US$)
    Table North America Opioid-Induced Constipation Revenue Market Share by Countries (2014-2019)
    Figure 2018 North America Opioid-Induced Constipation Revenue Market Share by Countries
    Figure United States Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure United States Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (K Units)
    Figure Canada Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Canada Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Mexico Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Mexico Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Table North America Opioid-Induced Constipation Sales by Product (2014-2019) (K Units)
    Table North America Opioid-Induced Constipation Sales Market Share by Product (2014-2019)
    Figure 2018 North America Opioid-Induced Constipation Market Share by Product
    Table North America Opioid-Induced Constipation Sales by End User (2014-2019) (K Units)
    Table North America Opioid-Induced Constipation Sales Market Share by End User (2014-2019)
    Figure 2018 North America Opioid-Induced Constipation Market Share by End User
    Figure Europe Opioid-Induced Constipation Sales Growth Rate 2014-2019 (K Units)
    Figure Europe Opioid-Induced Constipation Revenue Growth Rate 2014-2019 (Million US$)
    Table Europe Opioid-Induced Constipation Sales by Countries (2014-2019) (K Units)
    Table Europe Opioid-Induced Constipation Sales Market Share by Countries (2014-2019)
    Figure 2018 Europe Opioid-Induced Constipation Sales Market Share by Countries
    Table Europe Opioid-Induced Constipation Revenue by Countries (2014-2019) (Million US$)
    Table Europe Opioid-Induced Constipation Revenue Market Share by Countries (2014-2019)
    Figure 2018 Europe Opioid-Induced Constipation Revenue Market Share by Countries
    Figure Germany Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Germany Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure France Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure France Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure UK Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure UK Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Italy Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Italy Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Russia Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Russia Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Table Europe Opioid-Induced Constipation Sales by Product (2014-2019) (K Units)
    Table Europe Opioid-Induced Constipation Sales Market Share by Product (2014-2019)
    Figure 2018 Europe Opioid-Induced Constipation Market Share by Product
    Table Europe Opioid-Induced Constipation Sales by End User (2014-2019) (K Units)
    Table Europe Opioid-Induced Constipation Sales Market Share by End User (2014-2019)
    Figure 2018 Europe Opioid-Induced Constipation Market Share by End User
    Figure Asia Pacific Opioid-Induced Constipation Sales Growth Rate 2014-2019 (K Units)
    Figure Asia Pacific Opioid-Induced Constipation Revenue Growth Rate 2014-2019 (Million US$)
    Table Asia Pacific Opioid-Induced Constipation Sales by Countries (2014-2019) (K Units)
    Table Asia Pacific Opioid-Induced Constipation Sales Market Share by Countries (2014-2019)
    Figure 2018 Asia Pacific Opioid-Induced Constipation Sales Market Share by Countries
    Table Asia Pacific Opioid-Induced Constipation Revenue by Countries (2014-2019) (Million US$)
    Table Asia Pacific Opioid-Induced Constipation Revenue Market Share by Countries (2014-2019)
    Figure 2018 Asia Pacific Opioid-Induced Constipation Revenue Market Share by Countries
    Figure China Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure China Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Japan Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Japan Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Korea Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Korea Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure India Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure India Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Australia Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Australia Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Indonesia Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Indonesia Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Malaysia Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Malaysia Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Philippines Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Philippines Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Thailand Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Thailand Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Vietnam Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Vietnam Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Singapore Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Singapore Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Table Asia Pacific Opioid-Induced Constipation Sales by Product (2014-2019) (K Units)
    Table Asia Pacific Opioid-Induced Constipation Sales Market Share by Product (2014-2019)
    Figure 2018 Asia Pacific Opioid-Induced Constipation Market Share by Product
    Table Asia Pacific Opioid-Induced Constipation Sales by End User (2014-2019) (K Units)
    Table Asia Pacific Opioid-Induced Constipation Sales Market Share by End User (2014-2019)
    Figure 2018 Asia Pacific Opioid-Induced Constipation Market Share by End User
    Figure Central & South America Opioid-Induced Constipation Sales Growth Rate 2014-2019 (K Units)
    Figure Central & South America Opioid-Induced Constipation Revenue Growth Rate 2014-2019 (Million US$)
    Table Central & South America Opioid-Induced Constipation Sales by Countries (2014-2019) (K Units)
    Table Central & South America Opioid-Induced Constipation Sales Market Share by Countries (2014-2019)
    Figure 2018 Central & South America Opioid-Induced Constipation Sales Market Share by Countries
    Table Central & South America Opioid-Induced Constipation Revenue by Countries (2014-2019) (Million US$)
    Table Central & South America Opioid-Induced Constipation Revenue Market Share by Countries (2014-2019)
    Figure 2018 Central & South America Opioid-Induced Constipation Revenue Market Share by Countries
    Figure Brazil Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Brazil Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Argentina Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Argentina Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Table Central & South America Opioid-Induced Constipation Sales by Product (2014-2019) (K Units)
    Table Central & South America Opioid-Induced Constipation Sales Market Share by Product (2014-2019)
    Figure 2018 Central & South America Opioid-Induced Constipation Market Share by Product
    Table Central & South America Opioid-Induced Constipation Sales by End User (2014-2019) (K Units)
    Table Central & South America Opioid-Induced Constipation Sales Market Share by End User (2014-2019)
    Figure 2018 Central & South America Opioid-Induced Constipation Market Share by End User
    Figure Middle East and Africa Opioid-Induced Constipation Sales Growth Rate 2014-2019 (K Units)
    Figure Middle East and Africa Opioid-Induced Constipation Revenue Growth Rate 2014-2019 (Million US$)
    Table Middle East and Africa Opioid-Induced Constipation Sales by Countries (2014-2019) (K Units)
    Table Middle East and Africa Opioid-Induced Constipation Sales Market Share by Countries (2014-2019)
    Figure 2018 Middle East and Africa Opioid-Induced Constipation Sales Market Share by Countries
    Table Middle East and Africa Opioid-Induced Constipation Revenue by Countries (2014-2019) (Million US$)
    Table Middle East and Africa Opioid-Induced Constipation Revenue Market Share by Countries (2014-2019)
    Figure 2018 Middle East and Africa Opioid-Induced Constipation Revenue Market Share by Countries
    Figure GCC Countries Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure GCC Countries Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Turkey Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Turkey Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Egypt Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Egypt Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure South Africa Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure South Africa Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Table Middle East and Africa Opioid-Induced Constipation Sales by Product (2014-2019) (K Units)
    Table Middle East and Africa Opioid-Induced Constipation Sales Market Share by Product (2014-2019)
    Figure 2018 Middle East and Africa Opioid-Induced Constipation Market Share by Product
    Table Middle East and Africa Opioid-Induced Constipation Sales by End User (2014-2019) (K Units)
    Table Middle East and Africa Opioid-Induced Constipation Sales Market Share by End User (2014-2019)
    Figure 2018 Middle East and Africa Opioid-Induced Constipation Market Share by End User
    Table Takeda Pharmaceuticals Company Details
    Table Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
    Table Takeda Pharmaceuticals Recent Development
    Table Bayer Company Details
    Table Bayer Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
    Table Bayer Recent Development
    Table Sanofi Company Details
    Table Sanofi Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
    Table Sanofi Recent Development
    Table Mallinckrodt Company Details
    Table Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
    Table Mallinckrodt Recent Development
    Table Salix (Bausch Health) Company Details
    Table Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
    Table Salix (Bausch Health) Recent Development
    Table AstraZeneca Company Details
    Table AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
    Table AstraZeneca Recent Development
    Table Progenics Pharmaceuticals Company Details
    Table Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
    Table Progenics Pharmaceuticals Recent Development
    Table Purdue Pharm Company Details
    Table Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
    Table Purdue Pharm Recent Development
    Table Nektar Therapeutics Company Details
    Table Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
    Table Nektar Therapeutics Recent Development
    Table Daiichi Sankyo Company Details
    Table Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
    Table Daiichi Sankyo Recent Development
    Table Prestige Company Details
    Table GSK Company Details
    Table Shionogi Company Details
    Table Global Opioid-Induced Constipation Sales Forecast by Regions 2019-2025 (K Units)
    Table Global Opioid-Induced Constipation Sales Market Share Forecast by Regions 2019-2025
    Table Global Opioid-Induced Constipation Revenue Forecast by Regions 2019-2025 (Million US$)
    Table Global Opioid-Induced Constipation Revenue Market Share Forecast by Regions 2019-2025
    Table Global Opioid-Induced Constipation Sales Forecast by Product 2019-2025 (K Units)
    Table Global Opioid-Induced Constipation Sales Market Share Forecast by Product 2019-2025
    Table Global Opioid-Induced Constipation Revenue Forecast by Product 2019-2025 (Million US$)
    Table Global Opioid-Induced Constipation Revenue Market Share Forecast by Product 2019-2025
    Table Global Opioid-Induced Constipation Sales Forecast by End User 2019-2025 (K Units)
    Table Global Opioid-Induced Constipation Sales Market Share Forecast by End User 2019-2025
    Figure North America Opioid-Induced Constipation Sales Growth Rate Forecast (2019-2025) (K Units)
    Figure North America Opioid-Induced Constipation Revenue Growth Rate Forecast (2019-2025) (Million US$)
    Figure Europe Opioid-Induced Constipation Sales Growth Rate Forecast (2019-2025) (K Units)
    Figure Europe Opioid-Induced Constipation Revenue Growth Rate Forecast (2019-2025) (Million US$)
    Figure Asia Pacific Opioid-Induced Constipation Sales Growth Rate Forecast (2019-2025) (K Units)
    Figure Asia Pacific Opioid-Induced Constipation Revenue Growth Rate Forecast (2019-2025) (Million US$)
    Figure Central & South America Opioid-Induced Constipation Sales Growth Rate Forecast (2019-2025) (K Units)
    Figure Central & South America Opioid-Induced Constipation Revenue Growth Rate Forecast (2019-2025) (Million US$)
    Figure Middle East and Africa Opioid-Induced Constipation Sales Growth Rate Forecast (2019-2025) (K Units)
    Figure Middle East and Africa Opioid-Induced Constipation Revenue Growth Rate Forecast (2019-2025) (Million US$)
    Table Opioid-Induced Constipation Value Chain
    Table Opioid-Induced Constipation Customers List
    Table Opioid-Induced Constipation Distributors List
    Table Research Programs/Design for This Report
    Figure Bottom-up and Top-down Approaches for This Report
    Figure Data Triangulation
    Table Key Data Information from Secondary Sources
    Table Key Data Information from Primary Sources
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
In the last several years, global market of Opioid-Induced Constipation developed smoothly, with an average growth rate of 3.85% from the forecast period 2019 to 2025.
The classification of Opioid-Induced Constipation includes Methylnaltrexone Bromide, Lubiprostone, Naloxegol and other OTC drugs. The revenue proportion of Lubiprostone in 2017 is about 33%, and the proportion of OTC drugs is in about 34%.
Opioid-Induced Constipation is widely sold in Hospital, Pharmacy and other field. The most proportion of Opioid-Induced Constipation is sold in Pharmacy, and the proportion in 2017 is 45.99%.
The global Opioid-Induced Constipation market is valued at 2240 million US$ in 2018 and will reach 3060 million US$ by the end of 2025, growing at a CAGR of 4.6% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Opioid-Induced Constipation market based on company, product type, end user and key regions.

This report studies the global market size of Opioid-Induced Constipation in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Opioid-Induced Constipation in these regions.
This research report categorizes the global Opioid-Induced Constipation market by top players/brands, region, type and end user. This report also studies the global Opioid-Induced Constipation market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
    Takeda Pharmaceuticals
    Bayer
    Sanofi
    Mallinckrodt
    Salix (Bausch Health)
    AstraZeneca
    Progenics Pharmaceuticals
    Purdue Pharm
    Nektar Therapeutics
    Daiichi Sankyo
    Prestige
    GSK
    Shionogi

Market size by Product
    Methylnaltrexone Bromide
    Lubiprostone
    Naloxegol
    Others
Market size by End User
    Hospital
    Pharmacy

Market size by Region
    North America
        United States
        Canada
        Mexico
    Asia-Pacific
        China
        India
        Japan
        South Korea
        Australia
        Indonesia
        Singapore
        Malaysia
        Philippines
        Thailand
        Vietnam
    Europe
        Germany
        France
        UK
        Italy
        Spain
        Russia
    Central & South America
        Brazil
        Rest of Central & South America
    Middle East & Africa
        GCC Countries
        Turkey
        Egypt
        South Africa

The study objectives of this report are:
    To study and analyze the global Opioid-Induced Constipation market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
    To understand the structure of Opioid-Induced Constipation market by identifying its various subsegments.
    To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
    Focuses on the key global Opioid-Induced Constipation companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
    To project the value and sales volume of Opioid-Induced Constipation submarkets, with respect to key regions.
    To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Opioid-Induced Constipation are as follows:
    History Year: 2014-2018
    Base Year: 2018
    Estimated Year: 2019
    Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Opioid-Induced Constipation market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Read More
Table of Contents

1 Study Coverage
    1.1 Opioid-Induced Constipation Product
    1.2 Market Segments
    1.3 Key Manufacturers Covered
    1.4 Market by Type
        1.4.1 Global Opioid-Induced Constipation Market Size Growth Rate by Product
        1.4.2 Methylnaltrexone Bromide
        1.4.3 Lubiprostone
        1.4.4 Naloxegol
        1.4.5 Others
    1.5 Market by End User
        1.5.1 Global Opioid-Induced Constipation Market Size Growth Rate by End User
        1.5.2 Hospital
        1.5.3 Pharmacy
    1.6 Study Objectives
    1.7 Years Considered

2 Executive Summary
    2.1 Global Opioid-Induced Constipation Market Size
        2.1.1 Global Opioid-Induced Constipation Revenue 2014-2025
        2.1.2 Global Opioid-Induced Constipation Sales 2014-2025
    2.2 Opioid-Induced Constipation Growth Rate by Regions
        2.2.1 Global Opioid-Induced Constipation Sales by Regions
        2.2.2 Global Opioid-Induced Constipation Revenue by Regions

3 Breakdown Data by Manufacturers
    3.1 Opioid-Induced Constipation Sales by Manufacturers
        3.1.1 Opioid-Induced Constipation Sales by Manufacturers
        3.1.2 Opioid-Induced Constipation Sales Market Share by Manufacturers
        3.1.3 Global Opioid-Induced Constipation Market Concentration Ratio (CR5 and HHI)
    3.2 Opioid-Induced Constipation Revenue by Manufacturers
        3.2.1 Opioid-Induced Constipation Revenue by Manufacturers (2014-2019)
        3.2.2 Opioid-Induced Constipation Revenue Share by Manufacturers (2014-2019)
    3.3 Opioid-Induced Constipation Price by Manufacturers
    3.4 Opioid-Induced Constipation Manufacturing Base Distribution, Product Types
        3.4.1 Opioid-Induced Constipation Manufacturers Manufacturing Base Distribution, Headquarters
        3.4.2 Manufacturers Opioid-Induced Constipation Product Type
        3.4.3 Date of International Manufacturers Enter into Opioid-Induced Constipation Market
    3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
    4.1 Global Opioid-Induced Constipation Sales by Product
    4.2 Global Opioid-Induced Constipation Revenue by Product
    4.3 Opioid-Induced Constipation Price by Product

5 Breakdown Data by End User
    5.1 Overview
    5.2 Global Opioid-Induced Constipation Breakdown Data by End User

6 North America
    6.1 North America Opioid-Induced Constipation by Countries
        6.1.1 North America Opioid-Induced Constipation Sales by Countries
        6.1.2 North America Opioid-Induced Constipation Revenue by Countries
        6.1.3 United States
        6.1.4 Canada
        6.1.5 Mexico
    6.2 North America Opioid-Induced Constipation by Product
    6.3 North America Opioid-Induced Constipation by End User

7 Europe
    7.1 Europe Opioid-Induced Constipation by Countries
        7.1.1 Europe Opioid-Induced Constipation Sales by Countries
        7.1.2 Europe Opioid-Induced Constipation Revenue by Countries
        7.1.3 Germany
        7.1.4 France
        7.1.5 UK
        7.1.6 Italy
        7.1.7 Russia
    7.2 Europe Opioid-Induced Constipation by Product
    7.3 Europe Opioid-Induced Constipation by End User

8 Asia Pacific
    8.1 Asia Pacific Opioid-Induced Constipation by Countries
        8.1.1 Asia Pacific Opioid-Induced Constipation Sales by Countries
        8.1.2 Asia Pacific Opioid-Induced Constipation Revenue by Countries
        8.1.3 China
        8.1.4 Japan
        8.1.5 Korea
        8.1.6 India
        8.1.7 Australia
        8.1.8 Indonesia
        8.1.9 Malaysia
        8.1.10 Philippines
        8.1.11 Thailand
        8.1.12 Vietnam
        8.1.13 Singapore
    8.2 Asia Pacific Opioid-Induced Constipation by Product
    8.3 Asia Pacific Opioid-Induced Constipation by End User

9 Central & South America
    9.1 Central & South America Opioid-Induced Constipation by Countries
        9.1.1 Central & South America Opioid-Induced Constipation Sales by Countries
        9.1.2 Central & South America Opioid-Induced Constipation Revenue by Countries
        9.1.3 Brazil
    9.2 Central & South America Opioid-Induced Constipation by Product
    9.3 Central & South America Opioid-Induced Constipation by End User

10 Middle East and Africa
    10.1 Middle East and Africa Opioid-Induced Constipation by Countries
        10.1.1 Middle East and Africa Opioid-Induced Constipation Sales by Countries
        10.1.2 Middle East and Africa Opioid-Induced Constipation Revenue by Countries
        10.1.3 GCC Countries
        10.1.4 Turkey
        10.1.5 Egypt
        10.1.6 South Africa
    10.2 Middle East and Africa Opioid-Induced Constipation by Product
    10.3 Middle East and Africa Opioid-Induced Constipation by End User

11 Company Profiles
    11.1 Takeda Pharmaceuticals
        11.1.1 Takeda Pharmaceuticals Company Details
        11.1.2 Company Business Overview
        11.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
        11.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Products Offered
        11.1.5 Takeda Pharmaceuticals Recent Development
    11.2 Bayer
        11.2.1 Bayer Company Details
        11.2.2 Company Business Overview
        11.2.3 Bayer Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
        11.2.4 Bayer Opioid-Induced Constipation Products Offered
        11.2.5 Bayer Recent Development
    11.3 Sanofi
        11.3.1 Sanofi Company Details
        11.3.2 Company Business Overview
        11.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
        11.3.4 Sanofi Opioid-Induced Constipation Products Offered
        11.3.5 Sanofi Recent Development
    11.4 Mallinckrodt
        11.4.1 Mallinckrodt Company Details
        11.4.2 Company Business Overview
        11.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
        11.4.4 Mallinckrodt Opioid-Induced Constipation Products Offered
        11.4.5 Mallinckrodt Recent Development
    11.5 Salix (Bausch Health)
        11.5.1 Salix (Bausch Health) Company Details
        11.5.2 Company Business Overview
        11.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
        11.5.4 Salix (Bausch Health) Opioid-Induced Constipation Products Offered
        11.5.5 Salix (Bausch Health) Recent Development
    11.6 AstraZeneca
        11.6.1 AstraZeneca Company Details
        11.6.2 Company Business Overview
        11.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
        11.6.4 AstraZeneca Opioid-Induced Constipation Products Offered
        11.6.5 AstraZeneca Recent Development
    11.7 Progenics Pharmaceuticals
        11.7.1 Progenics Pharmaceuticals Company Details
        11.7.2 Company Business Overview
        11.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
        11.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Products Offered
        11.7.5 Progenics Pharmaceuticals Recent Development
    11.8 Purdue Pharm
        11.8.1 Purdue Pharm Company Details
        11.8.2 Company Business Overview
        11.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
        11.8.4 Purdue Pharm Opioid-Induced Constipation Products Offered
        11.8.5 Purdue Pharm Recent Development
    11.9 Nektar Therapeutics
        11.9.1 Nektar Therapeutics Company Details
        11.9.2 Company Business Overview
        11.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
        11.9.4 Nektar Therapeutics Opioid-Induced Constipation Products Offered
        11.9.5 Nektar Therapeutics Recent Development
    11.10 Daiichi Sankyo
        11.10.1 Daiichi Sankyo Company Details
        11.10.2 Company Business Overview
        11.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
        11.10.4 Daiichi Sankyo Opioid-Induced Constipation Products Offered
        11.10.5 Daiichi Sankyo Recent Development
    11.11 Prestige
    11.12 GSK
    11.13 Shionogi

12 Future Forecast
    12.1 Opioid-Induced Constipation Market Forecast by Regions
        12.1.1 Global Opioid-Induced Constipation Sales Forecast by Regions 2019-2025
        12.1.2 Global Opioid-Induced Constipation Revenue Forecast by Regions 2019-2025
    12.2 Opioid-Induced Constipation Market Forecast by Product
        12.2.1 Global Opioid-Induced Constipation Sales Forecast by Product 2019-2025
        12.2.2 Global Opioid-Induced Constipation Revenue Forecast by Product 2019-2025
    12.3 Opioid-Induced Constipation Market Forecast by End User
    12.4 North America Opioid-Induced Constipation Forecast
    12.5 Europe Opioid-Induced Constipation Forecast
    12.6 Asia Pacific Opioid-Induced Constipation Forecast
    12.7 Central & South America Opioid-Induced Constipation Forecast
    12.8 Middle East and Africa Opioid-Induced Constipation Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
    13.1 Market Opportunities and Drivers
    13.2 Market Challenges
    13.3 Market Risks/Restraints
    13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
    14.1 Value Chain Analysis
    14.2 Opioid-Induced Constipation Customers
    14.3 Sales Channels Analysis
        14.3.1 Sales Channels
        14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
    16.1 Research Methodology
        16.1.1 Methodology/Research Approach
        16.1.2 Data Source
    16.2 Author Details
    16.3 Disclaimer
Read More
List of Tables and Figures

    Figure Opioid-Induced Constipation Product Picture
    Table Opioid-Induced Constipation Market Segments
    Table Key Manufacturers Opioid-Induced Constipation Covered
    Table Global Opioid-Induced Constipation Market Size Growth Rate by Product 2019-2025 (K Units) & (Million US$)
    Figure Global Opioid-Induced Constipation Sales Market Share by Product 2014-2025
    Figure Methylnaltrexone Bromide Product Picture
    Table Major Manufacturers of Methylnaltrexone Bromide
    Figure Lubiprostone Product Picture
    Table Major Manufacturers of Lubiprostone
    Figure Naloxegol Product Picture
    Table Major Manufacturers of Naloxegol
    Figure Others Product Picture
    Table Major Manufacturers of Others
    Table Global Opioid-Induced Constipation Market Size Growth Rate by End User 2019-2025 (K Units)
    Figure Hospital
    Figure Pharmacy
    Figure Opioid-Induced Constipation Report Years Considered
    Figure Global Opioid-Induced Constipation Market Size 2014-2025 (Million US$)
    Figure Global Opioid-Induced Constipation Sales 2014-2025 (K Units)
    Table Global Opioid-Induced Constipation Market Size by Regions 2014-2019 (K Units) & (Million US$)
    Table Global Opioid-Induced Constipation Sales by Regions 2014-2019 (K Units)
    Table Global Opioid-Induced Constipation Sales Market Share by Regions 2014-2019
    Figure Global Opioid-Induced Constipation Sales Market Share by Regions 2014-2019
    Figure 2018 Global Opioid-Induced Constipation Sales Market Share by Regions
    Table Global Opioid-Induced Constipation Revenue by Regions 2014-2019 (Million US$)
    Table Global Opioid-Induced Constipation Revenue Market Share by Regions 2014-2019
    Figure Global Opioid-Induced Constipation Revenue Market Share by Regions 2014-2019
    Figure 2018 Global Opioid-Induced Constipation Revenue Market Share by Regions
    Table Global Opioid-Induced Constipation Sales by Manufacturers (2014-2019) (K Units)
    Table Global Opioid-Induced Constipation Sales Share by Manufacturers (2014-2019)
    Figure Global Opioid-Induced Constipation Sales Share by Manufacturers in 2018
    Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table Opioid-Induced Constipation Revenue by Manufacturers (2014-2019) (Million USD)
    Table Opioid-Induced Constipation Revenue Share by Manufacturers (2014-2019)
    Figure Opioid-Induced Constipation Value Share by Manufacturers in 2018
    Table Key Manufacturers Opioid-Induced Constipation Price (2014-2019) (USD/Unit)
    Table Opioid-Induced Constipation Manufacturers Manufacturing Base Distribution and Headquarters
    Table Manufacturers Opioid-Induced Constipation Product Type
    Table Date of International Manufacturers Enter into Opioid-Induced Constipation Market
    Table Manufacturers Mergers & Acquisitions, Expansion Plans
    Table Global Opioid-Induced Constipation Sales by Product (2014-2019) (K Units)
    Table Global Opioid-Induced Constipation Sales Share by Product (2014-2019)
    Figure Global Opioid-Induced Constipation Sales Market Share by Product (2014-2019)
    Figure Global Opioid-Induced Constipation Sales Market Share by Product in 2018
    Table Global Opioid-Induced Constipation Revenue by Product (2014-2019) (Million US$)
    Table Global Opioid-Induced Constipation Revenue Share by Product (2014-2019)
    Figure Global Opioid-Induced Constipation Revenue Market Share by Product (2014-2019)
    Figure Global Opioid-Induced Constipation Revenue Market Share by Product in 2018
    Table Opioid-Induced Constipation Price by Product 2014-2019 (USD/Unit)
    Table Global Opioid-Induced Constipation Sales by End User (2014-2019) (K Units)
    Table Global Opioid-Induced Constipation Sales Share by End User (2014-2019)
    Figure Global Sales Opioid-Induced Constipation Market Share by End User (2014-2019)
    Figure Global Sales Opioid-Induced Constipation Market Share by End User in 2018
    Figure North America Opioid-Induced Constipation Sales Growth Rate 2014-2019 (K Units)
    Figure North America Opioid-Induced Constipation Revenue Growth Rate 2014-2019 (Million US$)
    Table North America Opioid-Induced Constipation Sales by Countries (2014-2019) (K Units)
    Table North America Opioid-Induced Constipation Sales Market Share by Countries (2014-2019)
    Figure 2018 North America Opioid-Induced Constipation Sales Market Share by Countries
    Table North America Opioid-Induced Constipation Revenue by Countries (2014-2019) (Million US$)
    Table North America Opioid-Induced Constipation Revenue Market Share by Countries (2014-2019)
    Figure 2018 North America Opioid-Induced Constipation Revenue Market Share by Countries
    Figure United States Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure United States Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (K Units)
    Figure Canada Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Canada Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Mexico Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Mexico Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Table North America Opioid-Induced Constipation Sales by Product (2014-2019) (K Units)
    Table North America Opioid-Induced Constipation Sales Market Share by Product (2014-2019)
    Figure 2018 North America Opioid-Induced Constipation Market Share by Product
    Table North America Opioid-Induced Constipation Sales by End User (2014-2019) (K Units)
    Table North America Opioid-Induced Constipation Sales Market Share by End User (2014-2019)
    Figure 2018 North America Opioid-Induced Constipation Market Share by End User
    Figure Europe Opioid-Induced Constipation Sales Growth Rate 2014-2019 (K Units)
    Figure Europe Opioid-Induced Constipation Revenue Growth Rate 2014-2019 (Million US$)
    Table Europe Opioid-Induced Constipation Sales by Countries (2014-2019) (K Units)
    Table Europe Opioid-Induced Constipation Sales Market Share by Countries (2014-2019)
    Figure 2018 Europe Opioid-Induced Constipation Sales Market Share by Countries
    Table Europe Opioid-Induced Constipation Revenue by Countries (2014-2019) (Million US$)
    Table Europe Opioid-Induced Constipation Revenue Market Share by Countries (2014-2019)
    Figure 2018 Europe Opioid-Induced Constipation Revenue Market Share by Countries
    Figure Germany Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Germany Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure France Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure France Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure UK Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure UK Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Italy Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Italy Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Russia Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Russia Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Table Europe Opioid-Induced Constipation Sales by Product (2014-2019) (K Units)
    Table Europe Opioid-Induced Constipation Sales Market Share by Product (2014-2019)
    Figure 2018 Europe Opioid-Induced Constipation Market Share by Product
    Table Europe Opioid-Induced Constipation Sales by End User (2014-2019) (K Units)
    Table Europe Opioid-Induced Constipation Sales Market Share by End User (2014-2019)
    Figure 2018 Europe Opioid-Induced Constipation Market Share by End User
    Figure Asia Pacific Opioid-Induced Constipation Sales Growth Rate 2014-2019 (K Units)
    Figure Asia Pacific Opioid-Induced Constipation Revenue Growth Rate 2014-2019 (Million US$)
    Table Asia Pacific Opioid-Induced Constipation Sales by Countries (2014-2019) (K Units)
    Table Asia Pacific Opioid-Induced Constipation Sales Market Share by Countries (2014-2019)
    Figure 2018 Asia Pacific Opioid-Induced Constipation Sales Market Share by Countries
    Table Asia Pacific Opioid-Induced Constipation Revenue by Countries (2014-2019) (Million US$)
    Table Asia Pacific Opioid-Induced Constipation Revenue Market Share by Countries (2014-2019)
    Figure 2018 Asia Pacific Opioid-Induced Constipation Revenue Market Share by Countries
    Figure China Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure China Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Japan Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Japan Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Korea Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Korea Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure India Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure India Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Australia Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Australia Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Indonesia Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Indonesia Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Malaysia Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Malaysia Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Philippines Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Philippines Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Thailand Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Thailand Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Vietnam Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Vietnam Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Singapore Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Singapore Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Table Asia Pacific Opioid-Induced Constipation Sales by Product (2014-2019) (K Units)
    Table Asia Pacific Opioid-Induced Constipation Sales Market Share by Product (2014-2019)
    Figure 2018 Asia Pacific Opioid-Induced Constipation Market Share by Product
    Table Asia Pacific Opioid-Induced Constipation Sales by End User (2014-2019) (K Units)
    Table Asia Pacific Opioid-Induced Constipation Sales Market Share by End User (2014-2019)
    Figure 2018 Asia Pacific Opioid-Induced Constipation Market Share by End User
    Figure Central & South America Opioid-Induced Constipation Sales Growth Rate 2014-2019 (K Units)
    Figure Central & South America Opioid-Induced Constipation Revenue Growth Rate 2014-2019 (Million US$)
    Table Central & South America Opioid-Induced Constipation Sales by Countries (2014-2019) (K Units)
    Table Central & South America Opioid-Induced Constipation Sales Market Share by Countries (2014-2019)
    Figure 2018 Central & South America Opioid-Induced Constipation Sales Market Share by Countries
    Table Central & South America Opioid-Induced Constipation Revenue by Countries (2014-2019) (Million US$)
    Table Central & South America Opioid-Induced Constipation Revenue Market Share by Countries (2014-2019)
    Figure 2018 Central & South America Opioid-Induced Constipation Revenue Market Share by Countries
    Figure Brazil Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Brazil Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Argentina Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Argentina Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Table Central & South America Opioid-Induced Constipation Sales by Product (2014-2019) (K Units)
    Table Central & South America Opioid-Induced Constipation Sales Market Share by Product (2014-2019)
    Figure 2018 Central & South America Opioid-Induced Constipation Market Share by Product
    Table Central & South America Opioid-Induced Constipation Sales by End User (2014-2019) (K Units)
    Table Central & South America Opioid-Induced Constipation Sales Market Share by End User (2014-2019)
    Figure 2018 Central & South America Opioid-Induced Constipation Market Share by End User
    Figure Middle East and Africa Opioid-Induced Constipation Sales Growth Rate 2014-2019 (K Units)
    Figure Middle East and Africa Opioid-Induced Constipation Revenue Growth Rate 2014-2019 (Million US$)
    Table Middle East and Africa Opioid-Induced Constipation Sales by Countries (2014-2019) (K Units)
    Table Middle East and Africa Opioid-Induced Constipation Sales Market Share by Countries (2014-2019)
    Figure 2018 Middle East and Africa Opioid-Induced Constipation Sales Market Share by Countries
    Table Middle East and Africa Opioid-Induced Constipation Revenue by Countries (2014-2019) (Million US$)
    Table Middle East and Africa Opioid-Induced Constipation Revenue Market Share by Countries (2014-2019)
    Figure 2018 Middle East and Africa Opioid-Induced Constipation Revenue Market Share by Countries
    Figure GCC Countries Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure GCC Countries Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Turkey Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Turkey Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure Egypt Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure Egypt Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Figure South Africa Opioid-Induced Constipation Sales Growth Rate (2014-2019) (K Units)
    Figure South Africa Opioid-Induced Constipation Revenue Growth Rate (2014-2019) (Million US$)
    Table Middle East and Africa Opioid-Induced Constipation Sales by Product (2014-2019) (K Units)
    Table Middle East and Africa Opioid-Induced Constipation Sales Market Share by Product (2014-2019)
    Figure 2018 Middle East and Africa Opioid-Induced Constipation Market Share by Product
    Table Middle East and Africa Opioid-Induced Constipation Sales by End User (2014-2019) (K Units)
    Table Middle East and Africa Opioid-Induced Constipation Sales Market Share by End User (2014-2019)
    Figure 2018 Middle East and Africa Opioid-Induced Constipation Market Share by End User
    Table Takeda Pharmaceuticals Company Details
    Table Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
    Table Takeda Pharmaceuticals Recent Development
    Table Bayer Company Details
    Table Bayer Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
    Table Bayer Recent Development
    Table Sanofi Company Details
    Table Sanofi Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
    Table Sanofi Recent Development
    Table Mallinckrodt Company Details
    Table Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
    Table Mallinckrodt Recent Development
    Table Salix (Bausch Health) Company Details
    Table Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
    Table Salix (Bausch Health) Recent Development
    Table AstraZeneca Company Details
    Table AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
    Table AstraZeneca Recent Development
    Table Progenics Pharmaceuticals Company Details
    Table Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
    Table Progenics Pharmaceuticals Recent Development
    Table Purdue Pharm Company Details
    Table Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
    Table Purdue Pharm Recent Development
    Table Nektar Therapeutics Company Details
    Table Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
    Table Nektar Therapeutics Recent Development
    Table Daiichi Sankyo Company Details
    Table Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
    Table Daiichi Sankyo Recent Development
    Table Prestige Company Details
    Table GSK Company Details
    Table Shionogi Company Details
    Table Global Opioid-Induced Constipation Sales Forecast by Regions 2019-2025 (K Units)
    Table Global Opioid-Induced Constipation Sales Market Share Forecast by Regions 2019-2025
    Table Global Opioid-Induced Constipation Revenue Forecast by Regions 2019-2025 (Million US$)
    Table Global Opioid-Induced Constipation Revenue Market Share Forecast by Regions 2019-2025
    Table Global Opioid-Induced Constipation Sales Forecast by Product 2019-2025 (K Units)
    Table Global Opioid-Induced Constipation Sales Market Share Forecast by Product 2019-2025
    Table Global Opioid-Induced Constipation Revenue Forecast by Product 2019-2025 (Million US$)
    Table Global Opioid-Induced Constipation Revenue Market Share Forecast by Product 2019-2025
    Table Global Opioid-Induced Constipation Sales Forecast by End User 2019-2025 (K Units)
    Table Global Opioid-Induced Constipation Sales Market Share Forecast by End User 2019-2025
    Figure North America Opioid-Induced Constipation Sales Growth Rate Forecast (2019-2025) (K Units)
    Figure North America Opioid-Induced Constipation Revenue Growth Rate Forecast (2019-2025) (Million US$)
    Figure Europe Opioid-Induced Constipation Sales Growth Rate Forecast (2019-2025) (K Units)
    Figure Europe Opioid-Induced Constipation Revenue Growth Rate Forecast (2019-2025) (Million US$)
    Figure Asia Pacific Opioid-Induced Constipation Sales Growth Rate Forecast (2019-2025) (K Units)
    Figure Asia Pacific Opioid-Induced Constipation Revenue Growth Rate Forecast (2019-2025) (Million US$)
    Figure Central & South America Opioid-Induced Constipation Sales Growth Rate Forecast (2019-2025) (K Units)
    Figure Central & South America Opioid-Induced Constipation Revenue Growth Rate Forecast (2019-2025) (Million US$)
    Figure Middle East and Africa Opioid-Induced Constipation Sales Growth Rate Forecast (2019-2025) (K Units)
    Figure Middle East and Africa Opioid-Induced Constipation Revenue Growth Rate Forecast (2019-2025) (Million US$)
    Table Opioid-Induced Constipation Value Chain
    Table Opioid-Induced Constipation Customers List
    Table Opioid-Induced Constipation Distributors List
    Table Research Programs/Design for This Report
    Figure Bottom-up and Top-down Approaches for This Report
    Figure Data Triangulation
    Table Key Data Information from Secondary Sources
    Table Key Data Information from Primary Sources
Read More
SELECT A FORMAT
Added to Cart

Single User

Electronic (PDF)
$3900
This license allows only one user(purchaser of the report) to access the PDF.

Multi User

Electronic (PDF)
$5850
This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)
$7800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Strategic Venue Partners

RELATED REPORTS

Global Paclitaxel Injection Market Research Report 2021
Global Paclitaxel Injection Market Research Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-5J4435
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

Global Myotonic Dystrophy Medication Market Size Status and Forecast 2021 2027
Global Myotonic Dystrophy Medication Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-10R4400
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

Global Acne Treatment Drug Market Size Status and Forecast 2021 2027
Global Acne Treatment Drug Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-10B4399
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

Global Coronavirus Treatment Drugs Market Size Status and Forecast 2021 2027
Global Coronavirus Treatment Drugs Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-37M4166
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

0 Items
X
No items in the cart.
$0.0